Talis Biomedical (NASDAQ:TLIS – Get Rating) is one of 43 publicly-traded companies in the “Analytical instruments” industry, but how does it contrast to its rivals? We will compare Talis Biomedical to related companies based on the strength of its institutional ownership, dividends, earnings, analyst recommendations, profitability, risk and valuation.
Profitability
This table compares Talis Biomedical and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Talis Biomedical | -2,348.54% | -68.61% | -55.42% |
| Talis Biomedical Competitors | -273.31% | 238.74% | -17.34% |
Valuation & Earnings
This table compares Talis Biomedical and its rivals top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Talis Biomedical | $4.81 million | -$113.01 million | -0.12 |
| Talis Biomedical Competitors | $1.07 billion | -$256.75 million | 5.52 |
Insider and Institutional Ownership
47.1% of Talis Biomedical shares are owned by institutional investors. Comparatively, 54.9% of shares of all “Analytical instruments” companies are owned by institutional investors. 42.0% of Talis Biomedical shares are owned by insiders. Comparatively, 16.4% of shares of all “Analytical instruments” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Volatility and Risk
Talis Biomedical has a beta of 1.07, suggesting that its share price is 7% more volatile than the S&P 500. Comparatively, Talis Biomedical’s rivals have a beta of 1.04, suggesting that their average share price is 4% more volatile than the S&P 500.
Analyst Ratings
This is a summary of recent ratings and recommmendations for Talis Biomedical and its rivals, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Talis Biomedical | 0 | 0 | 0 | 0 | N/A |
| Talis Biomedical Competitors | 193 | 1104 | 1712 | 59 | 2.53 |
As a group, “Analytical instruments” companies have a potential upside of 11.97%. Given Talis Biomedical’s rivals higher possible upside, analysts plainly believe Talis Biomedical has less favorable growth aspects than its rivals.
Summary
Talis Biomedical rivals beat Talis Biomedical on 7 of the 10 factors compared.
Talis Biomedical Company Profile
Talis Biomedical Corporation operates as a molecular diagnostic company. The company is developing the Talis One system to address limitations of existing point-of-care diagnostic testing technologies for infectious diseases. It also offers Talis One COVID-19 Test System, which focuses on detection of SARS-CoV-2, the virus that causes COVID-19. In addition, it develops Talis One assay kit for respiratory infections, infections related to women's health, and sexually transmitted infections; and other tests for the detection of other respiratory infections, such as a respiratory panel test to detect influenza A, influenza B, and respiratory syncytial virus. Talis Biomedical Corporation was incorporated in 2013 and is headquartered in Menlo Park, California.
Receive News & Ratings for Talis Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Talis Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.
